Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eribulin mesylate |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Eribulin mesylate | Drug | Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Adverse Events (AEs) and Adverse Drug Reactions (ADRs) | up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Survival Rate at Year 2 | up to 2 years |
Not provided
Inclusion Criteria:
- Participants with soft tissue sarcoma who will receive eribulin mesylate per the approved indication in routine clinical practice
Exclusion Criteria:
- None
Not provided
Not provided
Not provided
Not provided
Participants with soft tissue sarcoma who will receive eribulin mesylate per the approved indication in routine clinical practice.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Osaka | Japan | |||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35546669 | Derived | Kawai A, Narahara H, Takahashi S, Nakamura T, Kobayashi H, Megumi Y, Matsuoka T, Kobayashi E. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study. BMC Cancer. 2022 May 11;22(1):528. doi: 10.1186/s12885-022-09527-y. | |
| 31365116 | Derived |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012509 | Sarcoma |
| ID | Term |
|---|---|
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C490954 | eribulin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Tokyo |
| Japan |
| Kobayashi E, Naito Y, Asano N, Maejima A, Endo M, Takahashi S, Megumi Y, Kawai A. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol. 2019 Oct 1;49(10):938-946. doi: 10.1093/jjco/hyz096. |